Repligen Corporation /
BioLife Solutions, Inc.
Repligen Corporation completed its deal for BioLife Solutions, Inc.
Source for the buyer and target: Repligen Corporation
For the buyer and target.
“WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company focused on bioprocessing technology leadership, today announced it has completed the previously announced acquisition of BioLife Solutions, Inc. (NASDAQ: BLFS, “BioLife”), a leading developer and supplier of cell processing tools and services for the cell and gene therapy market.”
Published 6 Oct 2026
Open the sourceWhat happened
The deal for BioLife Solutions, Inc. has closed, with Repligen Corporation as the buyer. [01]
The filing from Repligen Corporation is dated Oct. 6, 2026. [01]
Who is involved, and the source
Everything on this page comes from the source below, quoted word for word.
Advisers
Buy side
- Financial adviser to the buyerGoldman Sachs & Co. LLCSource: SEC filing, as of 6 Oct 2026
- Legal adviser to the buyerGoodwin Procter LLPSource: SEC filing, as of 6 Oct 2026
Target
- Financial adviser to the targetCenterview Partners, LLCSource: SEC filing, as of 6 Oct 2026
- Legal adviser to the targetK&L Gates LLPSource: SEC filing, as of 6 Oct 2026
Each adviser in its source's own words. An adviser's own announcement is labelled as one: it is not independent reporting. Advisers are not parties to the deal.
Repligen Corporation completed its deal for BioLife Solutions, Inc.
This document is the source for the companies, stage and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly